<DOC>
	<DOCNO>NCT00990522</DOCNO>
	<brief_summary>Standard care care twelve ( 12 ) weekly debridement . Subjects randomize weekly debridement group receive twelve ( 12 ) debridement twelve ( 12 ) week study . There two ( 2 ) subject group study . Subjects randomize either monthly debridement group weekly debridement group .</brief_summary>
	<brief_title>Study Efficacy Sharp Debridement Management Chronic Wounds</brief_title>
	<detailed_description>The primary objective study evaluate subject enrol randomized weekly sharp debridement group . The major secondary objective incidence complete wound closure Week 12 , rate healing , ulcer recurrence , wound characteristic , microbiologic information .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<criteria>1 . Subject must evidence fullthickness cutaneous wound least 30 day duration . 2 . Subject must least 18 year age . 3 . Subject must minimum life expectancy least 1 year determine Investigator . 4 . The study ulcer must 1 cm2 20 cm2 size . 5 . The study ulcer must present least 30 day study Day 7 . 6 . The subject 's Glycosylated hemoglobin ( HbA1C ) must equal less 10.0 % subject diagnose diabetes study Day 0 . 7 . The subject , legal guardian authorize representative must understand , sign dated IRB approve informed consent form . 8 . The subject must available evaluation weekly basis twelve ( 12 ) week study . Visits Week 13 Week 14 require initial wound healing , achieve study Week 11 12 . The Investigator evaluate group Week 16 . Subjects must available evaluation Week 16 . 9 . The subject 's TCpO2 must equal great 25 mm mercury periwound area ABI great 0.7 . 1 . Subject whose ulcer heal 30 % great evaluation Study day 7 postdebridement Study Day 0 determine wound measurement use ARANZ Silhouette 2 . A history alcohol substance abuse , within previous year , could , judgment Investigator , would interfere study compliance protocol requirement . 3 . Participation clinical trial evaluate investigational pharmaceutical , biologics device within 30 day admission study . 4 . Subject history receiving follow within last 30 day : systemic corticosteroid exceed total daily dose 20mg , immunosuppressive agent , radiation therapy chemotherapy . Anticipated use study period also exclude subject entry study . Topical inhale corticosteroid prohibit . 5 . Subjects medical comorbidities know affect wound heal end stage renal disease , severe hepatic insufficiency , vasculitis , HIV exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>sharp debridment</keyword>
	<keyword>patient full thickness wound great 30 day duration</keyword>
</DOC>